Bayer: Beijing branch heavily involved in its worldwide growth

(China Daily)
Updated: 2009-09-10 15:39

Bayer HealthCare Co Ltd's plant in Beijing was established in 1997. Since its opening, the plant has made great progress. Its robust production and sales philosophy has enabled it to gain a lead position in the development of the whole Bayer HealthCare group.

Bayer: Beijing branch heavily involved in its worldwide growth

In 2005, ex-factory sales of Bayer HealthCare (BHC) Beijing reached 1.1 billion yuan, swiftly topped by 1.5 billion yuan in 2006.

One year later, sales amounted to 2.3 billion yuan. The company is now confidently predicting sales revenue of 5 billion yuan for 2010.

Last year, its production in China increased by 50 percent. Glucobay, the company's lead product, became the treatment of choice for patients suffering from diabetes in China.

Additionally, it has also established 16 product lines.

In order to boost its production capacity, an extension project for the Beijing factory was launched on August 2006.

With strong support from the Beijing Economic Development Area (BDA), the project was successfully completed in October 2008.

The factory's production capacity increased four times following its expansion and is now equipped with state-of-the-art technology, including the fastest medicine packing production line in both China and the whole of the Asia-pacific area, allowing for a product throughput of 800 blisters per minute.

Special coverage:
Summer Davos 2009

With the expansion completed, the company is now looking to introduce four new packing lines and to produce three or four new products aimed at the requirements of the Chinese market.

The factory has also adopted an advanced cleaning system with all the rooms connected via a central conduit, preventing any contamination from the outside world.

The company's management has been at pains to maintain a good relationship with the various administrative sectors of the BDA.

It has also enjoyed the provision of high quality utilities thanks to the efforts of the BDA.

BHC has also been one of the many companies based in the area to take advantage of the BDA's raft of training initiatives, including sessions on security protocols and the handling of hazardous chemical materials.

Bernd Kalkert, vice general manager and head of product supply of Bayer HealthCare, China, commented: "The staff of the BDA really care about us. No matter what difficulties we encounter, the BDA has always lent a timely hand. Our company has also been recognized as a model business in terms of its safety precautions and fire protection standards.

"The management team of the BDA is highly responsible and their work is extremely professional. I've worked in Germany, the United States and China for many years and this is my third year working in the BDA. If you asked me to make a comparison of the services provided in all of those places, I would have to say that the BDA is the best and has given us huge support for all of our developments."

As with many other managers running companies within the BDA, Kalkert cites the area's location, infrastructure and environment as key reasons for re-locating there.

Summing up his company's plans for the future, he says: "I sincerely hope that the BDA and Bayer Schering Pharma will continue to jointly develop in the future and maintain their successful alliance."